Edition:
India

JCR Pharmaceuticals Co Ltd (4552.T)

4552.T on Tokyo Stock Exchange

5,830JPY
11:30am IST
Change (% chg)

¥-10 (-0.17%)
Prev Close
¥5,840
Open
¥5,800
Day's High
¥5,880
Day's Low
¥5,740
Volume
85,600
Avg. Vol
153,730
52-wk High
¥6,040
52-wk Low
¥2,133

Latest Key Developments (Source: Significant Developments)

JR-131, long-acting erythropoiesis-stimulating agent, demonstrates equivalence in phase III study
11:58am IST 

Jan 17 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it and JCR Pharmaceuticals Co Ltd <<<4552.T>>> jointly announced positive results of the phase III study for JR-131, a proposed biosimilar to darbepoetin alfa, a long-acting erythropoiesis-stimulating agent for the treatment of renal anemia .In the Phase III study initiated in August 2016, JR-131 demonstrated equivalence in efficacy and safety compared with darbepoetin.Accordingly, in a primary endpoint of efficacy, the equivalence was verified for variations in hemoglobin concentration and the similarity with regard to the safety profile was confirmed .  Full Article

Medipal Holdings signs contract to set up JV JCR USA with JCR Pharmaceuticals
Tuesday, 19 Dec 2017 

Dec 19(Reuters) - Medipal Holdings Corp <7459.T>:Says it signed a contract to set up a JV JCR USA Inc with JCR Pharmaceuticals Co Ltd <<<4552.T>>>.Says the JV will be established in January 2018.Says the company and JCR Pharmaceuticals will hold a 35 percent stake and a 65 percent stake in the JV respectively .  Full Article

JCR Pharmaceuticals to initiate development of JR-171, new drug candidate for Hurler Syndrome using J-Brain Cargo
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:Says it will initiate development of JR-171, new drug candidate for Hurler Syndrome using J-Brain Cargo.  Full Article

NanoCarrier and JCR conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:* Says it and NanoCarrier Co., Ltd <4571.T> conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines .* Under this agreement, Nanocarrier and JCR will integrate the unique technologies and knowledge of both companies, and aim to develop an innovative drug effectively delivered to the brain .  Full Article

PeptiDream signs collaborative research agreement with JCR Pharmaceuticals
Monday, 22 Feb 2016 

PeptiDream Inc:Says signed collaborative research agreement with JCR Pharmaceuticals for development of special cyclic peptide for target protein.  Full Article

JCR Pharmaceuticals and MEDIPAL HOLDINGS launch new product TEMCELL
Tuesday, 16 Feb 2016 

JCR Pharmaceuticals Co Ltd:The company and MEDIPAL HOLDINGS CORPORATION announced that TEMCELL® HS Inj. (human (allogeneic) bone marrow derived mesenchymal stem cells) which was approved for marketing in September last year, will become available on Feb. 24.Says will be distributed utilizing the ultra-low cold chain system developed jointly with MEDIPAL.  Full Article

BRIEF-Medipal Holdings signs contract to set up JV JCR USA with JCR Pharmaceuticals

* Says it signed a contract to set up a JV JCR USA Inc with JCR Pharmaceuticals Co Ltd